Key Takeaways
- Psychedelic-assisted therapy involves carefully controlled administration of substances like psilocybin or MDMA in conjunction with structured psychotherapy sessions, not recreational use.
- Multiple Phase 2 and Phase 3 clinical trials have demonstrated statistically significant reductions in alcohol consumption, tobacco use, and opioid relapse following psilocybin-assisted therapy.
- MDMA-assisted therapy received FDA Breakthrough Therapy designation for PTSD, a condition that commonly co-occurs with substance use disorders, with addiction trials underway.
- These therapies are hypothesized to work by promoting neuroplasticity, reducing default mode network over-activity, and creating a window of psychological flexibility that enhances therapeutic processing.
- Psychedelic therapy is not self-treatment; all trials take place under medical supervision with extensive preparation and integration therapy sessions that are central to outcomes.
- Trust SoCal in Orange County stays current with emerging research to ensure patients receive the most forward-thinking evidence-based care available; call (949) 280-8360 to learn more.
Introduction: A Scientific Renaissance in Addiction Treatment
After decades of near-complete regulatory prohibition, psychedelic compounds are experiencing a rigorous scientific renaissance that is reshaping how researchers and clinicians think about treating addiction. Institutions including Johns Hopkins University, NYU Langone Health, Imperial College London, and UCSF have published peer-reviewed clinical trial data demonstrating that carefully supervised psychedelic-assisted therapy can produce dramatic, durable reductions in substance use across a range of addictions. The FDA has granted Breakthrough Therapy designation to psilocybin for treatment-resistant depression and to MDMA for post-traumatic stress disorder, a regulatory milestone that signals exceptional preliminary clinical evidence and accelerates the pathway to approval.
It is essential to distinguish between the controlled, therapeutic use of psychedelics in clinical settings and recreational or self-directed use. In clinical trials, participants undergo extensive psychological screening, receive multiple preparatory therapy sessions, are supervised by trained clinicians throughout the dosing session, and participate in multiple integration sessions afterward to process the experience and consolidate gains. The therapeutic context, not simply the pharmacological effect of the compound, appears to be critical to outcomes. This insight has important implications for how these treatments might eventually be delivered if they receive regulatory approval.
At Trust SoCal, located in Fountain Valley in the heart of Orange County, our clinical team monitors emerging treatment research closely to ensure our patients benefit from the most current evidence-based approaches. While psychedelic-assisted therapies are not yet FDA-approved for addiction indications and are therefore not currently offered as clinical treatments, understanding this research helps patients and families contextualize the rapidly evolving landscape of addiction science. For information about our current evidence-based programs, contact us at (949) 280-8360.
Psilocybin Research: From Mystical Experience to Clinical Evidence
Psilocybin, the psychoactive compound found in certain species of mushrooms, has emerged as one of the most intensively studied psychedelic compounds in contemporary addiction research. A landmark 2022 study published in JAMA Psychiatry by researchers at NYU Langone Health found that two doses of psilocybin combined with motivational enhancement therapy reduced the number of heavy drinking days by 83 percent compared to 51 percent in the active placebo group among participants with alcohol use disorder. More remarkably, 48 percent of participants in the psilocybin group had completely stopped drinking by the end of the eight-month study period, compared to 24 percent of controls. These effect sizes are substantially larger than those observed with currently approved pharmacological treatments for alcohol use disorder.
Research on psilocybin for tobacco cessation, led by Matthew Johnson at Johns Hopkins, has produced equally striking results. In a pilot study and subsequent larger trial, approximately 80 percent of participants who received psilocybin-assisted therapy had quit smoking at the six-month follow-up, compared to the 15 to 35 percent cessation rates typically achieved with nicotine replacement therapy or varenicline. Participants described the psilocybin experience as among the most meaningful of their lives, frequently reporting profound shifts in their sense of identity and their relationship to tobacco. This subjective experience of personal transformation appears to correlate with treatment outcomes, suggesting that the psychological dimensions of the therapy are pharmacologically facilitated rather than incidental.
The neurobiological mechanisms underlying psilocybin's therapeutic effects in addiction are an area of active investigation. Psilocybin acts primarily as a serotonin 5-HT2A receptor agonist, producing its effects through modulation of the default mode network (DMN), the brain network associated with self-referential thinking, rumination, and habitual mental patterns. Neuroimaging studies have shown that psilocybin dramatically reduces DMN activity and connectivity, producing a state of increased cognitive flexibility that may allow entrenched patterns of addictive thinking to be examined and modified. This neurological effect, combined with the psychologically transformative subjective experience, appears to create a unique window of therapeutic opportunity that skilled clinicians can leverage to facilitate lasting behavioral change.
The FDA granted Breakthrough Therapy designation to psilocybin for treatment-resistant depression in 2018 and 2019, indicating that preliminary clinical evidence shows substantial improvement over existing therapies. Addiction-specific designations are anticipated as Phase 3 trial data matures.
Key Psilocybin Clinical Trials in Addiction
Several landmark clinical trials have examined psilocybin for specific substance use disorders, with promising results across multiple addiction types.
- Alcohol Use Disorder (NYU/Johns Hopkins): Phase 2 trials demonstrated 83% reduction in heavy drinking days with psilocybin plus therapy versus 51% with placebo plus therapy; Phase 3 trials are now underway.
- Tobacco Cessation (Johns Hopkins): Approximately 67-80% of participants maintained abstinence at 12-month follow-up, compared to 15-35% with standard pharmacotherapy.
- Opioid Use Disorder: Early-stage trials at Sunstone Therapies and other sites are examining psilocybin as an adjunct to buprenorphine treatment for opioid use disorder, with enrollment ongoing.
- Cocaine Use Disorder: Pilot studies are investigating psilocybin-assisted therapy for cocaine addiction, building on preclinical evidence suggesting psilocybin can reset incentive salience for drug cues.
How Psychedelic Therapy Is Structured: The Importance of Set and Setting
A common misconception about psychedelic therapy research is that the therapeutic effect is purely pharmacological, produced simply by ingesting the compound. In reality, decades of research and clinical experience have consistently demonstrated that the context in which the psychedelic experience occurs, what researchers call "set and setting," is as important as the compound itself. "Set" refers to the mindset of the participant, including their expectations, intentions, and psychological state. "Setting" encompasses the physical environment, the relationship with therapists, and the social context. Clinical trials invest enormous resources in optimizing both elements, which is why outcomes from supervised therapeutic settings differ dramatically from recreational use.
A typical course of psilocybin-assisted therapy in a clinical trial involves three to four preparatory sessions with therapists, one to three supervised dosing sessions lasting approximately six to eight hours each, and three to four integration sessions following the dosing days. During preparatory sessions, therapists help participants clarify their intentions, address fears, develop trust in the therapeutic relationship, and learn techniques for navigating challenging psychological experiences. During the dosing session, participants typically lie on a couch with eye shades and headphones playing carefully curated music while therapists provide supportive presence. Integration sessions are where much of the therapeutic work occurs, as participants work with therapists to make meaning of their experience and translate insights into behavioral change.
The role of the therapist in psychedelic-assisted therapy is fundamentally different from that in conventional psychotherapy. Therapists are trained to adopt a non-directive stance during the dosing session, trusting the participant's inner healing intelligence while providing support and grounding when needed. This approach, influenced by Carl Rogers's person-centered therapy and Stanislav Grof's transpersonal psychology, requires specialized training. Several institutions including the California Institute of Integral Studies and Synthesis Training are developing certified training programs for psychedelic-assisted therapy facilitators, anticipating the eventual regulatory approval of these treatments.
Never attempt psychedelic self-treatment for addiction. Outside of clinical trial settings, use of psilocybin carries significant risks including psychological destabilization, and lacks the preparatory and integration support that appears critical to therapeutic outcomes. Contact Trust SoCal at (949) 280-8360 for evidence-based treatment options available now.
Regulatory Landscape and the Path to Approval
The regulatory pathway for psychedelic therapies in the United States is complex and rapidly evolving. Psilocybin remains a Schedule I controlled substance under federal law, meaning it is classified as having no accepted medical use and high abuse potential. This classification has historically created significant barriers to research, though the FDA has shown increasing willingness to accommodate psychedelic research through mechanisms like the Breakthrough Therapy designation and expanded access programs. Oregon became the first U.S. state to legalize regulated psilocybin services through a ballot measure in 2020, and Colorado followed with a similar measure in 2022, creating state-level frameworks that exist in tension with federal law.
The FDA's rejection of MDMA-assisted therapy for PTSD in 2024, citing concerns about trial methodology and functional unblinding, served as an important reminder that regulatory approval requires exceptionally rigorous evidence even for compounds with promising preliminary data. This decision has led researchers to invest in developing better methodological approaches for psychedelic trials, including improved blinding strategies and more detailed assessment of functional outcomes. The field has responded constructively to this setback, with multiple organizations collaborating to design more robust Phase 3 trials that address the FDA's specific concerns.
Several cities and states have enacted or are considering policies that deprioritize enforcement of psychedelic laws, creating a patchwork legal landscape that can be confusing for individuals seeking treatment. It is crucial for anyone interested in psychedelic therapy to understand that participation in clinical trials is the only legal pathway in most jurisdictions, and that retreats operating outside the U.S. do not offer the screening, preparation, supervision, and integration support that clinical research settings provide. Trust SoCal's clinical team stays current with regulatory developments and can help patients understand legitimate avenues for accessing emerging treatments.
Current Legal Status of Key Psychedelic Compounds
The legal status of psychedelic compounds varies by substance and jurisdiction, creating important implications for research and access.
- Psilocybin: Schedule I federally; legal for licensed service centers in Oregon and Colorado; decriminalized in several cities including Denver, Oakland, Santa Cruz, and Ann Arbor.
- MDMA: Schedule I federally; available through FDA-approved clinical trials; Phase 3 trial data submitted to FDA; rejected in 2024, with redesigned trials planned.
- Ketamine: Not a traditional psychedelic; Schedule III controlled substance; FDA-approved as esketamine (Spravato) for treatment-resistant depression; widely used off-label in addiction contexts.
- Ibogaine: Schedule I federally; legal in Mexico and several other countries; trials underway at Stanford and other institutions with FDA-approved IND status.
What Psychedelic Research Means for Current Addiction Treatment
While psychedelic-assisted therapies remain investigational for most addiction indications in the United States, the research has already had significant influence on conventional addiction treatment. The emphasis on psychological set and setting in psychedelic research has reinforced the importance of therapeutic alliance, treatment environment, and patient preparation in traditional addiction care. The integration model, in which the therapeutic work happens largely after the primary intervention through careful reflection and meaning-making, has enriched approaches to working with all transformative therapeutic experiences, not just psychedelic ones.
Psychedelic research has also rekindled scientific interest in the role of mystical or transpersonal experiences in recovery. Twelve-step programs have long emphasized spiritual awakening as a mechanism of change, and psychedelic researchers have found that the intensity of the mystical-type experience during psilocybin sessions correlates significantly with treatment outcomes. This finding bridges the gap between spiritual approaches to recovery and neuroscience, suggesting that experiences of profound connectedness, ego dissolution, and transcendence may activate neurobiological mechanisms of healing regardless of whether they are induced by meditation, community, or pharmacological means.
The growing body of psychedelic research is also driving increased investment in understanding the neuroscience of consciousness, self-referential processing, and psychological flexibility, all of which are highly relevant to addiction. Insights from this research are informing the development of non-pharmacological interventions that may approximate some of the effects of psychedelic therapy, such as advanced mindfulness protocols, certain breathing techniques, and immersive virtual reality experiences. At Trust SoCal, we integrate the lessons of emerging research into our comprehensive treatment programs, even when specific technologies are not yet clinically available. Call (949) 280-8360 to discuss how our approach to treatment incorporates the latest scientific understanding.
The potential of psychedelic therapy to address addiction is not about replacing existing treatments but about adding a powerful new tool that addresses dimensions of the condition that current approaches do not fully reach.
— Dr. Matthew Johnson, Professor of Psychiatry, Johns Hopkins University
Evidence-Based Care Available Now at Trust SoCal
While psychedelic-assisted therapies are not yet standard-of-care treatments for addiction, a robust array of evidence-based interventions is available now at Trust SoCal in Fountain Valley, Orange County. These include medication-assisted treatment with FDA-approved medications such as buprenorphine, naltrexone, and acamprosate, which have extensive evidence bases demonstrating reduced mortality, relapse, and cravings. Our behavioral therapy offerings include cognitive-behavioral therapy, dialectical behavior therapy, motivational interviewing, and contingency management, each with strong research support across multiple substance use disorders.
Our clinical team also integrates several therapies that share mechanistic features with psychedelic-assisted therapy, including mindfulness-based relapse prevention, trauma-focused therapies such as EMDR, and somatic approaches that work with the body's role in addiction and recovery. These modalities address the psychological flexibility, emotional processing, and meaning-making dimensions that psychedelic research has highlighted as central to durable recovery. For patients who are interested in participating in clinical research, our team can provide information about local and national clinical trials and help determine eligibility.
Located at 16537 Elm Cir, Fountain Valley, CA 92708, Trust SoCal offers a comprehensive continuum of care from medical detoxification through residential treatment, partial hospitalization, intensive outpatient programming, and aftercare support. Our multidisciplinary team works collaboratively to match each patient with the combination of treatments most likely to support sustained recovery based on their individual needs, history, and goals. We accept most major insurance plans and are committed to making high-quality, science-informed care accessible to individuals and families throughout Orange County and Southern California. Call (949) 280-8360 to take the first step.
Trust SoCal Editorial Team, Clinical Review Board
Editorial & Clinical Review